Bolt Biotherapeutics Files 8-K on Security Holder Vote Matters

TL;DR

Bolt Biotherapeutics is holding a shareholder vote on June 12th. Big decisions ahead.

AI Summary

On June 12, 2024, Bolt Biotherapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorporated in Delaware, is based in Redwood City, California, and operates in the pharmaceutical preparations industry.

Why It Matters

This filing indicates a significant corporate event where security holders will vote on important company matters, potentially impacting future strategy and shareholder value.

Risk Assessment

Risk Level: medium — Filings related to security holder votes can signal significant corporate actions or changes that may affect the company's future direction and stock price.

Key Numbers

• 001-39988 — SEC File Number (Identifies the company's filing with the SEC.)
• 47-2804636 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Bolt Biotherapeutics, Inc. (company) — Registrant
• June 12, 2024 (date) — Earliest event reported
• Redwood City, California (location) — Principal Executive Offices
• 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share BOLT The Nasdaq Global Se

Filing Documents

• bolt-20240612.htm (8-K) — 51KB
• 0000950170-24-073501.txt ( ) — 166KB
• bolt-20240612.xsd (EX-101.SCH) — 25KB
• bolt-20240612_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 12, 2024, Bolt Biotherapeutics, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting") to consider and vote on the two proposals set forth below, each of which is described in greater detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 26, 2024. A total of 38,127,740 shares of the Company's common stock were entitled to vote as of April 15, 2024, the record date for the Annual Meeting, of which 25,928,185 shares were represented in person or by proxy at the Annual Meeting. Proxies for the Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management's solicitation. a. The following director nominees were elected to serve as Class III members of the Company's board of directors until the Company's 2027 Annual Meeting of Stockholders, or until their respective successor is duly elected and qualified, or until their respective death, resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Kathleen LaPorte 12,706,287 3,990,176 9,231,722 Nicole Onetto, M.D. 12,819,050 3,880,294 9,228,841 b. The selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified. Votes For Votes Against Votes Abstaining 23,736,566 2,032,686 158,933

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Bolt Biotherapeutics, Inc. Date: June 14, 2024 By: /s/ William P. Quinn William P. Quinn President, Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR